Skip to main content

Table 4 Surface under the cumulative ranking curve results of the outcomes

From: Comparative efficacy of eight oral Chinese patent medicines for dilated cardiomyopathy with heart failure: a Bayesian network meta-analysis

Intervention

CER

LVEF

LVEDD

6MWT

BNP

CO

QLQX + CAM

56%

39.5%

37.3%

56.6%

74.5%

72.6%

WX + CAM

54.1%

39.3%

95.9%

70.8%

–

–

TXL + CAM

60.2%

67.6%

47.3%

66.8%

34.5%

75.4%

QSYQ + CAM

80.2%

44.1%

42.6%

–

–

–

SXBX + CAM

26.8%

73.7%

71.2%

47.9%

73.6%

50.4%

YXST + CAM

65.2%

97.2%

58.3%

–

–

–

YXSC + CAM

23.7%

18.8%

45.2%

55.3%

–

–

GTTL + CAM

81.3%

69.3%

49.8%

–

–

43.4%

CAM

.2.4%

0.6%

2.4%

2.7%

17.5%

26.4%

  1. QLQX Qili Qiangxin capsule, WX Wenxin granule, TXL Tongxinluo capsule, QSYQ Qishen Yiqi dropping pill, SXBX Shexiang Baoxin pill, YXST Yangxinshi tablet, YXSC Yixinshu capsule, GTTL Getong Tongluo capsule, CAM complementary and alternative medicine, CER clinical effectiveness rate, LVEF left ventricular ejection fraction, LVEDD left ventricular end-diastolic dimension, 6MWT six-min walk test, BNP brain natriuretic peptide, CO cardiac output